8-K: USANA Health Sciences Reports Lower Q3 Sales and Updates Fiscal Year Outlook

USANA Health Sciences announced a decrease in third-quarter sales and earnings per share, while also revising its full-year outlook due to continued macroeconomic headwinds.

Summary

• USANA Health Sciences reported third-quarter net sales of $200 million, a 6% decrease compared to $213 million in the same quarter of the previous year.
• Diluted earnings per share (EPS) for the third quarter were $0.56, down from $0.59 in Q3 2023.
• The company has updated its fiscal year 2024 net sales outlook to approximately $850 million, down from the previous range of $850 million to $880 million.
• The full-year diluted EPS outlook has also been revised to $2.45, compared to the previous range of $2.40 to $2.55.
• Active customers decreased by 3% year-over-year to 452,000.
• The Asia Pacific region accounted for 80% of consolidated net sales, with Greater China contributing $102 million.
• The company generated $30 million in operating cash flow during the third quarter and ended with $365 million in cash and cash equivalents.
• USANA did not repurchase any shares during the quarter, with $62 million remaining under the current share repurchase authorization.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the decrease in sales, earnings, and customer numbers, as well as the lowered full-year outlook. However, the company's strong cash position and focus on strategic initiatives provide some positive aspects.

Positives

• Gross margin increased by 30 basis points to 80.4% due to lower material costs and price increases.
• The company generated $30 million in operating cash flow during the quarter.
• USANA ended the quarter with a strong cash position of $365 million and no debt.
• Two new products were launched, indicating a focus on product innovation.
• The company is actively engaging with sales leaders and implementing new initiatives.
• Selling, General and Administrative expenses decreased by $2.0 million year-over-year on an absolute basis.

Negatives

• Net sales decreased by 6% year-over-year to $200 million.
• Diluted EPS decreased by 5% year-over-year to $0.56.
• The company lowered its full-year net sales and diluted EPS outlook.
• Active customers decreased by 3% year-over-year.
• Sales in Greater China decreased by 4% year-over-year.
• Sales in North Asia decreased by 15% year-over-year.
• Sales in the Americas and Europe region decreased by 7% year-over-year.
• The effective tax rate increased to 43.0% year-to-date.

Risks

• The company faces continued macroeconomic headwinds impacting consumer spending and customer acquisition.
• There is a risk that the company's strategic initiatives may not produce the desired results.
• The company is exposed to risks associated with governmental regulation of its products and direct selling model.
• Geopolitical relations and conflicts could negatively impact the company's operations.
• Fluctuations in foreign currency exchange rates pose a risk to financial results.
• There is a risk of material breaches of information technology systems.
• The company faces risks associated with commencing operations in India and future international expansion.

Future Outlook

The company expects the operating environment to remain challenging in the fourth quarter and plans to increase promotional activity to drive sales. They are monitoring stimulus initiatives in China but do not expect a significant impact in the near term. USANA remains focused on its long-term strategic initiatives and believes it is well-positioned to benefit from the growing consumer focus on health and wellness.

Management Comments

• Third quarter operating results reflected continued top line headwinds across many of our key markets, said Jim Brown, President and Chief Executive Officer.
• Our sales force continued to face challenges in attracting new customers as consumer sentiment remained cautious, including in our largest market, mainland China.
• We are monitoring the recently-announced stimulus initiatives in China, but we do not expect them to meaningfully impact our near-term operating results, said Doug Hekking, Chief Financial Officer.
• Notwithstanding the macroeconomic challenges we have faced in 2024, our business fundamentals remain strong.
• We remain focused on executing the five key initiatives that underpin our long-term strategy.
• We will continue to invest in organic strategic initiatives with an Associate-first mentality, expand and enhance our best-in-class products, and evaluate accretive business development opportunities.

Industry Context

The results reflect a challenging environment for direct selling companies, particularly those with significant exposure to China, where consumer spending is under pressure. The company's focus on product innovation and engagement with sales leaders aligns with industry trends aimed at retaining and attracting customers in a competitive market.

Comparison to Industry Standards

• USANA's 6% decline in net sales is similar to other direct selling companies facing macroeconomic headwinds, particularly in Asia.
• Nu Skin Enterprises, another direct selling company, reported a 10% decline in revenue in their most recent quarter, indicating a broader trend in the industry.
• Herbalife Nutrition also reported a decline in net sales, highlighting the challenges in the nutritional supplement market.
• USANA's focus on product innovation and digital tools is consistent with industry efforts to adapt to changing consumer preferences.
• The company's strong cash position is a positive differentiator compared to some competitors with higher debt levels.

Stakeholder Impact

• Shareholders will be impacted by the lower sales and earnings, as well as the reduced full-year outlook.
• Associates may face challenges in attracting new customers due to the current economic environment.
• Customers may benefit from new product launches and promotional activities.
• Employees may be affected by the company's performance and strategic changes.

Next Steps

• The company will continue to execute on its five key strategic initiatives.
• USANA plans to modestly increase promotional activity in the fourth quarter.
• The company will continue to invest in product innovation and commercialization.
• Management will hold a conference call on October 23, 2024, to discuss the results.

Key Dates

Keywords

USANA, Health Sciences, Direct Selling, Nutritional Supplements, Q3 2024, Earnings, Net Sales, EPS, Active Customers, China, Asia Pacific, Macroeconomic, Financial Results